Verrica Pharmaceuticals Inc. (VRCA) Tops Q4 EPS by 6c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q4 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $340 thousand versus the consensus estimate of $532.75 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Western Union Co. (WU) Reiterated at Market Perform by Citizens amid Retail Decline
• Microsoft (MSFT) Reiterated at Market Outperform by Citizens as Cowork Rollout Announced